Eccogene

Eccogene is a biotechnology company dedicated to the discovery and development of innovative therapies for metabolic and immune-related diseases. The company operates in the biopharmaceutical sector, targeting conditions such as cardiometabolic diseases and non-alcoholic fatty liver disease (NAFLD). Eccogene's business model revolves around translational medicine, which aims to translate scientific research into effective clinical treatments. The company generates revenue through licensing agreements and partnerships with major pharmaceutical companies. For instance, Eccogene recently entered an exclusive license agreement with AstraZeneca to develop and commercialize a small molecule GLP-1 receptor agonist, ECC5004, for cardiometabolic diseases, securing an initial upfront payment of $185 million. Eccogene serves a global market, focusing on unmet medical needs and leveraging its scientific expertise to bring differentiated therapies to patients. The company has also raised significant financing, including over 100 million RMB in a recent funding round led by Oriza Seed and Delos Capital, with participation from new and existing investors.

Keywords: biotechnology, drug discovery, metabolic diseases, immune-related diseases, translational medicine, cardiometabolic, NAFLD, GLP-1 receptor agonist, licensing agreements, biopharmaceutical.